Rutgers Business School’s MBA in Pharmaceutical Management was recently ranked as one of the top 10 MBA programs for Health Care/Pharmaceuticals/Biotechnology in the world, based on a survey done by Find-MBA.com.
According to a press release from Rutgers, the program earned its ranking due to its success in assisting MBA grads to earn internships and jobs focused in the health care, pharmaceuticals and biotechnology industries. This was a function of the quality of the program, complemented by Rutgers Business School’s proximity to, and relationship with, top tier pharmaceutical companies and several large hospitals in the region.
Rutgers is located in the heart of New Jersey’s so-called “bio-pharma corridor,” and collaborates with pharmaceutical companies including Bayer Healthcare, Bristol-Myers Squibb, Eisai, Johnson & Johnson, Merck and Novartis, which sit on its Board of Advisors for the Pharma MBA Program.
Gibbons Intellectual Property Department Chairman, David E. De Lorenzi, sits on the school’s Board, and Gibbons attorneys Sheila F. McShane, Estelle Tsevdos and Charles Gaglia serve as faculty for the Rutgers Pharma MBA executive management programs.